IRE-1α inhibitors

US11337956B2 · kind B2 · utility

Assignee

• Fosun Orinove Pharmatech, Inc. · CN

Inventors

• Qingping Zeng · Thousand Oaks, US
• Andras Toro · Oxnard, US
• John Bruce Patterson · Ventura, US
• Warren Wade · San Diego, US
• Zoltan Zubovics · Budapest, HU
• Yun Yang · Tianjin, CN
• Zhipeng Wu · Tianjin, CN

Key dates

• Filing date: Jun 3, 2019
• Grant date: May 24, 2022
• Expiry date: Jun 3, 2039

Classification

• Technology area (CPC Y): Emerging Cross-Sectional Technologies
• CPC primary: Y02A50/30
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Compounds which directly inhibit IRE-1α activity in vitro, prodrugs, and pharmaceutically acceptable salts thereof. Such compounds and prodrugs are useful for treating diseases associated with the unfolded protein response or with regulated IRE1-dependent decay (RIDD) and can be used as single agents or in combination therapies.